India Exchange Filings

Zydus Therapeutics Phase 2b Saroglitazar Results

Zydus Lifesciences Ltd reports Phase 2b MASH trial results for saroglitazar, with 39.1% achieving disease resolution on 4 mg

  • At week 52, resolution of steatohepatitis without worsening fibrosis was 39.1% with 4 mg and 32.4% with 2 mg, versus 13.7% on placebo.
  • The 4 mg dose’s improvement in fibrosis by at least one stage was not statistically significant.
  • Treatment was generally well tolerated, with no significant weight gain or drug-induced liver injury signal; saroglitazar remains investigational for MASH.
  • Results are slated for presentation at AASLD 2026.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.